Momenta says planned runs at manufacturing partner GSK could be reattributed to another product as it ends development of M923, a biosimilar candidate to Humira (adalimumab). In October 2018, Momenta Pharmaceuticals said it was exiting the biosimilars space following a lengthy strategic review process to concentrate on its novel biologics pipeline. The company told Scrip it would terminate all but two late-stage programs, a biosimilar version of AbbVie’ blockbuster Humira (adalimumab) and a biosimilar of Regeneron’s Eylea (aflibercept). Ten months…